DURECT Corporation (DRRX) Position Cut by New York State Common Retirement Fund

New York State Common Retirement Fund reduced its position in DURECT Corporation (NASDAQ:DRRX) by 40.7% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 102,300 shares of the specialty pharmaceutical company’s stock after selling 70,283 shares during the period. New York State Common Retirement Fund owned about 0.07% of DURECT worth $160,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. State of Wisconsin Investment Board acquired a new stake in DURECT during the second quarter worth approximately $151,000. Rhumbline Advisers lifted its position in DURECT by 12.0% during the second quarter. Rhumbline Advisers now owns 175,604 shares of the specialty pharmaceutical company’s stock worth $274,000 after acquiring an additional 18,871 shares during the last quarter. Bank of New York Mellon Corp lifted its position in DURECT by 4.1% during the second quarter. Bank of New York Mellon Corp now owns 370,387 shares of the specialty pharmaceutical company’s stock worth $578,000 after acquiring an additional 14,553 shares during the last quarter. TIAA CREF Investment Management LLC lifted its position in DURECT by 2.2% during the first quarter. TIAA CREF Investment Management LLC now owns 423,625 shares of the specialty pharmaceutical company’s stock worth $445,000 after acquiring an additional 9,289 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in DURECT by 2.6% during the first quarter. Geode Capital Management LLC now owns 985,630 shares of the specialty pharmaceutical company’s stock worth $1,034,000 after acquiring an additional 24,869 shares during the last quarter. Institutional investors and hedge funds own 46.13% of the company’s stock.

Several equities research analysts have issued reports on the stock. HC Wainwright restated a “hold” rating on shares of DURECT in a research report on Thursday, November 2nd. ValuEngine downgraded shares of DURECT from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 21st. Laidlaw cut their price objective on shares of DURECT from $3.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, October 20th. Finally, Stifel Nicolaus downgraded shares of DURECT from a “buy” rating to a “hold” rating in a research report on Friday, October 20th.

Shares of DURECT Corporation (DRRX) opened at $1.12 on Monday. The company has a quick ratio of 1.57, a current ratio of 1.67 and a debt-to-equity ratio of 1.46. DURECT Corporation has a 1 year low of $0.74 and a 1 year high of $2.17.

DURECT (NASDAQ:DRRX) last issued its quarterly earnings data on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.09. The firm had revenue of $20.75 million during the quarter, compared to the consensus estimate of $5.09 million. DURECT had a negative net margin of 62.57% and a negative return on equity of 419.65%. equities research analysts forecast that DURECT Corporation will post -0.14 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “DURECT Corporation (DRRX) Position Cut by New York State Common Retirement Fund” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://transcriptdaily.com/2017/11/27/durect-corporation-drrx-position-cut-by-new-york-state-common-retirement-fund.html.

About DURECT

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Institutional Ownership by Quarter for DURECT (NASDAQ:DRRX)

Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply